A 2026 target-trial emulation evaluated menopausal hormone therapy and cardiovascular risk in perimenopausal and recently postmenopausal women with vasomotor symptoms.

JAMA Internal Medicine published the study on September 8, 2026.

What this evidence adds

Results depend on age, timing, formulation and individual history; there is no single approach for every woman.

Source: JAMA Internal Medicine, September 8, 2026.